The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
Biohaven Pharmaceutical Holding Co. Ltd.’s oral calcitonin gene-related peptide (CGRP) inhibitor Nurtec ODT (rimegepant) will soon be the third new therapy to launch this year as an acute treatment for migraine attacks now that the US Food and Drug Administration has approved the drug.
New Haven, CT-based Biohaven announced the approval on 27 February and the company plans to launch the drug in early March, but it did not disclose Nurtec’s list price
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
As CEO Anderson backs high prices for innovative drugs in Europe
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.
The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.
The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.
